Dusty punch cards and an eternal enigma: high-density lipoproteins and atherosclerosis

Area of Science:

• Cardiovascular Science
• Lipid Metabolism
• Pharmacology

Background:

• Decades of evidence suggest high-density lipoproteins (HDL) protect against atherosclerosis.
• The precise biochemistry, function, and clinical significance of HDL remain incompletely understood.
• The link between HDL and heart attacks was first described over 55 years ago.

Purpose of the Study:

• To evaluate the clinical significance of HDL in cardiovascular disease.
• To address the enigmatic aspects of HDL biochemistry and function.
• To examine the impact of recent clinical trial results on HDL-targeted therapies.

Main Methods:

• Review of epidemiological, clinical, and experimental evidence.
• Analysis of data from recent clinical trials involving nicotinic acid.
• Examination of outcomes from trials using cholesteryl ester transfer protein (CETP) inhibitors.

Main Results:

• Unexpected results from recent clinical trials have challenged established concepts.
• Pharmacological interventions aimed at increasing HDL cholesterol have yielded controversial outcomes.
• The protective role of elevated HDL against vascular disease is now under scrutiny.

Conclusions:

• The assumption that raising HDL cholesterol reduces vascular disease risk requires re-evaluation.
• Further research is needed to clarify the complex role of HDL in atherosclerosis.
• The clinical utility of therapies targeting HDL requires further investigation.